The bitter end: The ubiquitin-proteasome system and cardiac dysfunction

Cam Patterson, Christopher Ike, Park W. Willis IV, George A. Stouffer, Monte Willis

Research output: Contribution to journalReview article

67 Citations (Scopus)

Abstract

Many elements contribute to congestive heart failure: changes in perfusion, hemodynamic stresses, alterations in calcium metabolism, and dysregulation of cell signaling pathways. Intervention in these processes forms the basis for current heart failure therapies. Nevertheless, heart failure is primarily a disease of wear and tear; despite everything we know about cardiac physiology and the clinical manifestations of heart failure, only in rare instances does therapy for heart failure normalize cardiac function. Proteins are especially prone to the forces of wear and tear in the heart because they are the primary mechanisms for stress sensing and force generation. Recent evidence supports a role for protein damage and impaired clearance of damaged proteins in the pathophysiology of human heart failure syndromes. The process of monitoring and protecting cardiac cells from accumulation of damaged proteins is known as protein quality control, and the molecular chaperone and ubiquitin-proteasome systems are the primary effectors of this process. Insights from protein quality-control strategies may lead to new concepts about prevention and treatment of human heart failure. This review provides a general overview of these pathways and their known and postulated roles in human heart failure syndromes, with a focus on providing a clinically oriented understanding of these fundamental mechanisms.

Original languageEnglish (US)
Pages (from-to)1456-1463
Number of pages8
JournalCirculation
Volume115
Issue number11
DOIs
StatePublished - Mar 1 2007
Externally publishedYes

Fingerprint

Proteasome Endopeptidase Complex
Ubiquitin
Heart Failure
Proteins
Tears
Quality Control
Molecular Chaperones
Therapeutics
Perfusion
Hemodynamics
Calcium

Keywords

  • Apoptosis
  • Heart failure
  • Hypertrophy
  • Ischemia
  • Proteins

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

The bitter end : The ubiquitin-proteasome system and cardiac dysfunction. / Patterson, Cam; Ike, Christopher; Willis IV, Park W.; Stouffer, George A.; Willis, Monte.

In: Circulation, Vol. 115, No. 11, 01.03.2007, p. 1456-1463.

Research output: Contribution to journalReview article

Patterson, Cam ; Ike, Christopher ; Willis IV, Park W. ; Stouffer, George A. ; Willis, Monte. / The bitter end : The ubiquitin-proteasome system and cardiac dysfunction. In: Circulation. 2007 ; Vol. 115, No. 11. pp. 1456-1463.
@article{c4d54525543b4717b3365e62d5945efd,
title = "The bitter end: The ubiquitin-proteasome system and cardiac dysfunction",
abstract = "Many elements contribute to congestive heart failure: changes in perfusion, hemodynamic stresses, alterations in calcium metabolism, and dysregulation of cell signaling pathways. Intervention in these processes forms the basis for current heart failure therapies. Nevertheless, heart failure is primarily a disease of wear and tear; despite everything we know about cardiac physiology and the clinical manifestations of heart failure, only in rare instances does therapy for heart failure normalize cardiac function. Proteins are especially prone to the forces of wear and tear in the heart because they are the primary mechanisms for stress sensing and force generation. Recent evidence supports a role for protein damage and impaired clearance of damaged proteins in the pathophysiology of human heart failure syndromes. The process of monitoring and protecting cardiac cells from accumulation of damaged proteins is known as protein quality control, and the molecular chaperone and ubiquitin-proteasome systems are the primary effectors of this process. Insights from protein quality-control strategies may lead to new concepts about prevention and treatment of human heart failure. This review provides a general overview of these pathways and their known and postulated roles in human heart failure syndromes, with a focus on providing a clinically oriented understanding of these fundamental mechanisms.",
keywords = "Apoptosis, Heart failure, Hypertrophy, Ischemia, Proteins",
author = "Cam Patterson and Christopher Ike and {Willis IV}, {Park W.} and Stouffer, {George A.} and Monte Willis",
year = "2007",
month = "3",
day = "1",
doi = "10.1161/CIRCULATIONAHA.106.649863",
language = "English (US)",
volume = "115",
pages = "1456--1463",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "11",

}

TY - JOUR

T1 - The bitter end

T2 - The ubiquitin-proteasome system and cardiac dysfunction

AU - Patterson, Cam

AU - Ike, Christopher

AU - Willis IV, Park W.

AU - Stouffer, George A.

AU - Willis, Monte

PY - 2007/3/1

Y1 - 2007/3/1

N2 - Many elements contribute to congestive heart failure: changes in perfusion, hemodynamic stresses, alterations in calcium metabolism, and dysregulation of cell signaling pathways. Intervention in these processes forms the basis for current heart failure therapies. Nevertheless, heart failure is primarily a disease of wear and tear; despite everything we know about cardiac physiology and the clinical manifestations of heart failure, only in rare instances does therapy for heart failure normalize cardiac function. Proteins are especially prone to the forces of wear and tear in the heart because they are the primary mechanisms for stress sensing and force generation. Recent evidence supports a role for protein damage and impaired clearance of damaged proteins in the pathophysiology of human heart failure syndromes. The process of monitoring and protecting cardiac cells from accumulation of damaged proteins is known as protein quality control, and the molecular chaperone and ubiquitin-proteasome systems are the primary effectors of this process. Insights from protein quality-control strategies may lead to new concepts about prevention and treatment of human heart failure. This review provides a general overview of these pathways and their known and postulated roles in human heart failure syndromes, with a focus on providing a clinically oriented understanding of these fundamental mechanisms.

AB - Many elements contribute to congestive heart failure: changes in perfusion, hemodynamic stresses, alterations in calcium metabolism, and dysregulation of cell signaling pathways. Intervention in these processes forms the basis for current heart failure therapies. Nevertheless, heart failure is primarily a disease of wear and tear; despite everything we know about cardiac physiology and the clinical manifestations of heart failure, only in rare instances does therapy for heart failure normalize cardiac function. Proteins are especially prone to the forces of wear and tear in the heart because they are the primary mechanisms for stress sensing and force generation. Recent evidence supports a role for protein damage and impaired clearance of damaged proteins in the pathophysiology of human heart failure syndromes. The process of monitoring and protecting cardiac cells from accumulation of damaged proteins is known as protein quality control, and the molecular chaperone and ubiquitin-proteasome systems are the primary effectors of this process. Insights from protein quality-control strategies may lead to new concepts about prevention and treatment of human heart failure. This review provides a general overview of these pathways and their known and postulated roles in human heart failure syndromes, with a focus on providing a clinically oriented understanding of these fundamental mechanisms.

KW - Apoptosis

KW - Heart failure

KW - Hypertrophy

KW - Ischemia

KW - Proteins

UR - http://www.scopus.com/inward/record.url?scp=34147131267&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147131267&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.106.649863

DO - 10.1161/CIRCULATIONAHA.106.649863

M3 - Review article

C2 - 17372187

AN - SCOPUS:34147131267

VL - 115

SP - 1456

EP - 1463

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 11

ER -